Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jan 6;21(1):33-8.
doi: 10.1016/j.cmet.2014.12.009.

Activation of human brown adipose tissue by a β3-adrenergic receptor agonist

Aaron M Cypess  1 , Lauren S Weiner  2 , Carla Roberts-Toler  2 , Elisa Franquet Elía  3 , Skyler H Kessler  2 , Peter A Kahn  4 , Jeffrey English  3 , Kelly Chatman  5 , Sunia A Trauger  5 , Alessandro Doria  6 , Gerald M Kolodny  3
Affiliations
Clinical Trial

Activation of human brown adipose tissue by a β3-adrenergic receptor agonist

Aaron M Cypess et al. Cell Metab. .

Abstract

Increasing energy expenditure through activation of endogenous brown adipose tissue (BAT) is a potential approach to treat obesity and diabetes. The class of β3-adrenergic receptor (AR) agonists stimulates rodent BAT, but this activity has never been demonstrated in humans. Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a β3-AR agonist currently approved to treat overactive bladder, to stimulate BAT as compared to placebo. Mirabegron led to higher BAT metabolic activity as measured via (18)F-fluorodeoxyglucose ((18)F-FDG) using positron emission tomography (PET) combined with computed tomography (CT) in all twelve healthy male subjects (p = 0.001), and it increased resting metabolic rate (RMR) by 203 ± 40 kcal/day (+13%; p = 0.001). BAT metabolic activity was also a significant predictor of the changes in RMR (p = 0.006). Therefore, a β3-AR agonist can stimulate human BAT thermogenesis and may be a promising treatment for metabolic disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Metabolic Effects of the β3-AR Agonist Mirabegron
(A) PET images of a 21-year-old man who was given placebo (left) or 200 mg of the β3-AR agonist mirabegron (right). Twelve male subjects were given placebo or 200 mg mirabegron. (B) BAT metabolic activity as reflected by 18F-FDG uptake. (C) Resting metabolic rate. (D) Heart rate. (E) Systolic BP. (F) Diastolic BP. Each circle represents a single subject, and the numbers correspond to subject identification number in Figure S2. The dashes represent the mean. See also Figure S2.
Figure 2
Figure 2. Tissue Glucose Uptake
18F-FDG uptake in the twelve volunteers when given placebo or 200 mg mirabegron is shown for different tissues. Each circle represents a single subject. (A) Myocardium. (B) Subcutaneous WAT. (C) Skeletal muscle. (D) Liver. See also Table S1.
Figure 3
Figure 3. Predictors of Resting Metabolic Rate
(A) Placebo-induced BAT activity. (B) Two-hundred milligram mirabegron-induced BAT activity. (C) Body fat mass with placebo. (D) Body fat mass with 200 mg mirabegron. See also Figure S3.
See this image and copyright information in PMC

References

    1. Arch JR. Challenges in β(3)-Adrenoceptor Agonist Drug Development. Ther Adv Endocrinol Metab. 2011;2:59–64. - PMC - PubMed
    1. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200–205. - PubMed
    1. Carey AL, Formosa MF, Van Every B, Bertovic D, Eikelis N, Lambert GW, Kalff V, Duffy SJ, Cherk MH, Kingwell BA. Ephedrine activates brown adipose tissue in lean but not obese humans. Diabetologia. 2013;56:147–155. - PubMed
    1. Cawthorne MA, Sennitt MV, Arch JR, Smith SA. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. Am J Clin Nutr. 1992;55(Suppl):252S–257S. - PubMed
    1. Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24:1447–1458. - PMC - PubMed

Publication types

MeSH terms